Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites
- Autores
- Arias, Hugo Rubén; Feuerbach, D; Ortells, Marcelo Oscar
- Año de publicación
- 2017
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- In this work, the interaction of (±)-bupropion [(±)-BP] and (±)-2-(N-tert-butylamino)-3’-iodo-4’- azidopropiophenone [(±)-SADU-3-72] with the human (h) α3β4 nicotinic acetylcholine receptor (AChR) is determined by functional and structural approaches. The Ca2+ influx results indicate that (±)-BP inhibits hα3β4 AChRs with ~2-fold lower potency than that for (±)-SADU-3-72, indicating that this photoreactive analog can be used to further characterize the (±)-BP binding sites. The competition binding results show that (±)-BP binds to the [3 H]imipramine sites at desensitized hα3β4 AChRs with ~4-fold higher affinity compared to the resting state. Molecular docking results indicate that both enantiomers of BP and SADU-3-72, in the protonated state, interact with luminal and non-luminal sites. BP interacts with a luminal site which overlaps that for imipramine, and with non-luminal sites located in the transmembrane domain (TMD) at interfacial (+α3/-β4) and α3 intrasubunit sites, and in the TMD-ECD (extracellular domain) junction at the +β4/-α3 and +β4/-β4 interfaces. Our results are consistent with a hα3β4 model where BP and SADU-3-72 bind to overlapping non-luminal sites as well as non-overlapping luminal sites, probably in physiological conditions. This work expands on previous studies supporting the notion that structurally different antidepressants produce their clinical effects by inhibiting distinct AChR subtypes.
Fil: Arias, Hugo Rubén. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Morón; Argentina
Fil: Feuerbach, D. Novartis Institutes for Biomedical Research; Suiza
Fil: Ortells, Marcelo Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Morón; Argentina - Materia
-
NICOTINIC RECEPTOR
BUPROPION
MOLECULAR MODELING - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/73221
Ver los metadatos del registro completo
id |
CONICETDig_d5d1e0d1c9f13fcad448a9685eaf6197 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/73221 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sitesArias, Hugo RubénFeuerbach, DOrtells, Marcelo OscarNICOTINIC RECEPTORBUPROPIONMOLECULAR MODELINGhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3In this work, the interaction of (±)-bupropion [(±)-BP] and (±)-2-(N-tert-butylamino)-3’-iodo-4’- azidopropiophenone [(±)-SADU-3-72] with the human (h) α3β4 nicotinic acetylcholine receptor (AChR) is determined by functional and structural approaches. The Ca2+ influx results indicate that (±)-BP inhibits hα3β4 AChRs with ~2-fold lower potency than that for (±)-SADU-3-72, indicating that this photoreactive analog can be used to further characterize the (±)-BP binding sites. The competition binding results show that (±)-BP binds to the [3 H]imipramine sites at desensitized hα3β4 AChRs with ~4-fold higher affinity compared to the resting state. Molecular docking results indicate that both enantiomers of BP and SADU-3-72, in the protonated state, interact with luminal and non-luminal sites. BP interacts with a luminal site which overlaps that for imipramine, and with non-luminal sites located in the transmembrane domain (TMD) at interfacial (+α3/-β4) and α3 intrasubunit sites, and in the TMD-ECD (extracellular domain) junction at the +β4/-α3 and +β4/-β4 interfaces. Our results are consistent with a hα3β4 model where BP and SADU-3-72 bind to overlapping non-luminal sites as well as non-overlapping luminal sites, probably in physiological conditions. This work expands on previous studies supporting the notion that structurally different antidepressants produce their clinical effects by inhibiting distinct AChR subtypes.Fil: Arias, Hugo Rubén. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Morón; ArgentinaFil: Feuerbach, D. Novartis Institutes for Biomedical Research; SuizaFil: Ortells, Marcelo Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Morón; ArgentinaSmart Science & Technology LLC2017-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/73221Arias, Hugo Rubén; Feuerbach, D; Ortells, Marcelo Oscar; Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites; Smart Science & Technology LLC; Neurotransmitter; 5; 12-2017; 1-112375-2440CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.14800/nt.1631info:eu-repo/semantics/altIdentifier/url/www.smartscitech.com/index.php/NT/article/view/1631info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:02:31Zoai:ri.conicet.gov.ar:11336/73221instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:02:32.153CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites |
title |
Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites |
spellingShingle |
Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites Arias, Hugo Rubén NICOTINIC RECEPTOR BUPROPION MOLECULAR MODELING |
title_short |
Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites |
title_full |
Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites |
title_fullStr |
Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites |
title_full_unstemmed |
Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites |
title_sort |
Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites |
dc.creator.none.fl_str_mv |
Arias, Hugo Rubén Feuerbach, D Ortells, Marcelo Oscar |
author |
Arias, Hugo Rubén |
author_facet |
Arias, Hugo Rubén Feuerbach, D Ortells, Marcelo Oscar |
author_role |
author |
author2 |
Feuerbach, D Ortells, Marcelo Oscar |
author2_role |
author author |
dc.subject.none.fl_str_mv |
NICOTINIC RECEPTOR BUPROPION MOLECULAR MODELING |
topic |
NICOTINIC RECEPTOR BUPROPION MOLECULAR MODELING |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
In this work, the interaction of (±)-bupropion [(±)-BP] and (±)-2-(N-tert-butylamino)-3’-iodo-4’- azidopropiophenone [(±)-SADU-3-72] with the human (h) α3β4 nicotinic acetylcholine receptor (AChR) is determined by functional and structural approaches. The Ca2+ influx results indicate that (±)-BP inhibits hα3β4 AChRs with ~2-fold lower potency than that for (±)-SADU-3-72, indicating that this photoreactive analog can be used to further characterize the (±)-BP binding sites. The competition binding results show that (±)-BP binds to the [3 H]imipramine sites at desensitized hα3β4 AChRs with ~4-fold higher affinity compared to the resting state. Molecular docking results indicate that both enantiomers of BP and SADU-3-72, in the protonated state, interact with luminal and non-luminal sites. BP interacts with a luminal site which overlaps that for imipramine, and with non-luminal sites located in the transmembrane domain (TMD) at interfacial (+α3/-β4) and α3 intrasubunit sites, and in the TMD-ECD (extracellular domain) junction at the +β4/-α3 and +β4/-β4 interfaces. Our results are consistent with a hα3β4 model where BP and SADU-3-72 bind to overlapping non-luminal sites as well as non-overlapping luminal sites, probably in physiological conditions. This work expands on previous studies supporting the notion that structurally different antidepressants produce their clinical effects by inhibiting distinct AChR subtypes. Fil: Arias, Hugo Rubén. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Morón; Argentina Fil: Feuerbach, D. Novartis Institutes for Biomedical Research; Suiza Fil: Ortells, Marcelo Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Morón; Argentina |
description |
In this work, the interaction of (±)-bupropion [(±)-BP] and (±)-2-(N-tert-butylamino)-3’-iodo-4’- azidopropiophenone [(±)-SADU-3-72] with the human (h) α3β4 nicotinic acetylcholine receptor (AChR) is determined by functional and structural approaches. The Ca2+ influx results indicate that (±)-BP inhibits hα3β4 AChRs with ~2-fold lower potency than that for (±)-SADU-3-72, indicating that this photoreactive analog can be used to further characterize the (±)-BP binding sites. The competition binding results show that (±)-BP binds to the [3 H]imipramine sites at desensitized hα3β4 AChRs with ~4-fold higher affinity compared to the resting state. Molecular docking results indicate that both enantiomers of BP and SADU-3-72, in the protonated state, interact with luminal and non-luminal sites. BP interacts with a luminal site which overlaps that for imipramine, and with non-luminal sites located in the transmembrane domain (TMD) at interfacial (+α3/-β4) and α3 intrasubunit sites, and in the TMD-ECD (extracellular domain) junction at the +β4/-α3 and +β4/-β4 interfaces. Our results are consistent with a hα3β4 model where BP and SADU-3-72 bind to overlapping non-luminal sites as well as non-overlapping luminal sites, probably in physiological conditions. This work expands on previous studies supporting the notion that structurally different antidepressants produce their clinical effects by inhibiting distinct AChR subtypes. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-12 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/73221 Arias, Hugo Rubén; Feuerbach, D; Ortells, Marcelo Oscar; Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites; Smart Science & Technology LLC; Neurotransmitter; 5; 12-2017; 1-11 2375-2440 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/73221 |
identifier_str_mv |
Arias, Hugo Rubén; Feuerbach, D; Ortells, Marcelo Oscar; Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites; Smart Science & Technology LLC; Neurotransmitter; 5; 12-2017; 1-11 2375-2440 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.14800/nt.1631 info:eu-repo/semantics/altIdentifier/url/www.smartscitech.com/index.php/NT/article/view/1631 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Smart Science & Technology LLC |
publisher.none.fl_str_mv |
Smart Science & Technology LLC |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842269761152483328 |
score |
13.13397 |